<strong>Senate advocates NHIS coverage for kidney diseases</strong>

<strong>Senate advocates NHIS coverage for kidney diseases</strong>

The Senate, on Thursday, called on the Federal Government to expand its coverage the National Health Insurance Scheme to cover patients with chronic kidney disease.

It also urged the FG and other stakeholders to launch extensive public awareness campaigns on kidney disease prevention, risks and unavailable treatment.

The Senate’s resolutions were sequel to the adoption of a motion sponsored by Senator Abdulaziz Yar’Adua (APC, Katsina Central) under personal explanation during Tuesday’s plenary.

In his presentation, Yar’Adua said recent statistics from the Nigerian Association of Nephrology revealed that 25 million Nigerians were living with kidney diseases.

He said, “Chronic kidney disease constitutes about 40 per cent of tertiary hospitals in Nigeria and is a significant contributor to daily hospital admissions.

“The cost of dialysis sessions in Nigeria ranges from 20,000 to 50,000 per session leading to low adherent rates due to financial constraints.

“The alternative to dialysis which is kidney transplant is financially unattainable for many with the cost exceeding N6.5m.

About author

You might also like

Increase commitment to children, Lagos Governor urges parents, medical practitioners

The Lagos State governor, Akinwumi Ambode has enjoined the healthcare practitioners, parents, and guidance to live up to their responsibilities of monitoring and observing children in order to detect issues

Lagos screens over 50, 000 women for breast, cervical cancers  

No fewer than 53,762 women have been screened so far for cervical and breast cancers by the Lagos State government in a free programme it commenced last year.   The

BREAKING NEWS 0 Comments

Merck, Pfizer, Syndax Collaborate to evaluate combination drug for ovarian cancer

Multinational pharmaceutical companies, Merck, Pfizer and Syndax Pharmaceuticals, Inc. have entered into a collaboration agreement to evaluate avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Syndax’s

0 Comments

No Comments Yet!

You can be first to comment this post!

Leave a Reply